

Index

- ablation 82, 144, 151
- absorbance 297, 299–301, 303–4
- absorption 114–15, 210, 238–39
- acoustic radiation force (ARF) 153
- active pharmaceutical ingredients (APIs) 116–17, 122–23
- adherent junctions (AJs) 191
- adhesion 90–91, 93
 - gliomatose cells 189
- AFM, *see* atomic force microscopy
- agents
 - anticancer 28, 35, 56, 204–5
 - capping 243, 287, 308
 - cavitation 156–57
 - chemotherapeutic 126, 196, 225, 274
 - chemotherapy 202, 280
 - phase transfer 242
- aggregation 9, 31, 209–10, 224, 239, 241, 244, 247, 287
- AgNPs, *see* silver nanoparticles
- AIF, *see* apoptosis-inducing factor
- AJs, *see* adherent junctions
- alimentary canal 145
- analysis of variance (ANOVA) 300–301
- ANOVA, *see* analysis of variance
- anticancer activity 81, 87, 93, 128
- anticancer drugs, liposomal 27
- anticancer drug therapy 106
- anticancer immunity 108
- anticancer responses 111
- anticancer therapy 105, 128
- anticancer treatment 96
- antigen presenting cells (APCs) 84, 93, 107–8, 129, 210
- antigens
 - multiple cancer cell membrane 92
 - tumor-associated 127
- anti-HER2 PLD 34
- antioxidants 209, 227
- antitumor drug delivery therapy 77
- antitumor therapies 121, 193, 202
- APCs, *see* antigen presenting cells
- APIs, *see* active pharmaceutical ingredients
- apoptosis 46–49, 51–54, 57–59, 61, 63, 152, 200, 208, 225, 230, 247–48, 253, 280–81, 286
 - cancer 151
 - damage-mediated 63
 - intrinsic pathway of 49
 - mitochondrial pathway of 52, 58
 - stress-induced 53–54
 - TRAIL-mediated 228
- apoptosis-inducing factor (AIF) 49
- apoptosis induction 45–48, 50, 52–54, 56, 58, 60, 62, 64
- apoptosome 49–50
- apoptosome cleaves 49–50
- apoptotic nuclei 286
- apoptotic protease 49–50
- aptamers 83, 114, 255
- ARF, *see* acoustic radiation force
- astrocytomas 186
- atomic force microscopy (AFM) 224
- AuNPs/GNPs, *see* gold nanoparticles

- AuNSs, *see* gold nanoshells
 avidin 157–58
- Bacillus Calmette Guérin (BCG)
 106–7
- bacteria-derived minicells 35
- BBB, *see* blood-brain barrier
- BBTB, *see* blood-brain tumor barrier
- BCG, *see* Bacillus Calmette Guérin
- blood-brain barrier (BBB) 10, 26, 34, 84, 116–17, 121–22, 164, 186–87, 189, 191–98, 204–8, 210–11, 229
- blood-brain tumor barrier (BBTB) 191
- blood circulation 25, 54–56, 77, 79, 254
- bloodstream 79, 85, 90
- blood vessels 10, 57, 85, 148, 152, 158, 190, 205
- bovine serum albumin (BSA) 208, 287
- brain tumors 186, 196, 203
 malignant 186
 primary 185
- brain tumor therapy 212
- breast cancer 27–28, 61, 64, 82, 86–88, 93–94, 126–27, 281
 drug-resistant 91
- breast cancer MCF7 cells 59
- BSA, *see* bovine serum albumin
- cancer
 bladder 106
 cervical 83, 94
 colon 228
 gastric 88, 280
 genitourinary 106
 lung 64, 281
 neck 106
 non-responsive 128
 ovarian 33
 pancreatic 33, 36
 rectal 64
- cancer ablation 145, 151
- cancer biomarker 24
- cancer cell death 247
- cancer cell lines 83
- cancer cell membrane 23, 93
- cancer cell membrane coatings 92
- cancer cell membrane protein 92
- cancer cell necrosis 251
- cancer cell proliferation 227
- cancer cell recognition 108
- cancer cells 13, 24–26, 38, 57, 61, 76, 78, 89, 91–94, 106–8, 110–12, 126, 129, 145, 152, 188, 205, 207, 236, 247–49, 251–53, 256, 277
 chemoresistant 280
 cultured 200
 cultured glioma 201
 metastatic 86
- cancer cells membranes 77, 86
- cancer cell survival 46
- cancer diagnosis 245, 278
- cancer immunotherapy 92, 106–7, 111
- cancer lesions 145
- cancer LNCaP cells 59
- cancer metastasis 91
- cancer microenvironments 127, 159
- cancer nanotechnology
 applications 250
- cancer nanotherapeutics 25
- cancer patients 14, 54, 250
- cancer radiation therapy 250

- cancer radiotherapy 123
- cancer SDT process 162
- cancer sonodynamic therapy 162
- cancer stem cells (CSCs) 203–4
- cancer-targeted therapy 12–13
- cancer therapy 13–14, 24, 37, 45–46, 48, 50, 52, 54, 56–58, 60, 62, 64–65, 76, 85, 92, 107, 111, 119, 144–45, 200, 236–37, 242, 246, 250–51, 256, 258
 - active targeted 254
 - conventional 46
 - promising agents for 235–36, 238, 240, 244, 246, 248, 250, 252, 254, 258
 - sonothermal 144
 - ultrasound 145
 - ultrasound-related micro-/nanoparticle 162, 164
- cancer therapy modalities 248–49
- cancer tissues 62, 148, 151, 162
 - local 161
- cancer vaccines 92
- carbon nanotubes (CNs) 7, 26, 186, 191, 195, 201–3, 210
- carboplatin 64
- carmustine 196
- carrier-mediated transport (CMT) 193–94
- caspases, effector 48–49
- cavitation effects 145–46, 151–52, 159
- CCD, *see* central composite design
- CED, *see* convention enhanced delivery
- cell adhesion 190–91
- cell death 46–48, 54, 248, 253
 - programmed 46–47, 49
- cell membrane biomimetic strategies 79, 81, 83, 85, 87, 89, 91, 93
- cell membrane coatings 77, 95–96
- cell-penetrating peptides (CPPs) 196, 205
- cells
 - abnormal 12, 24
 - apoptotic 47
 - astrocyte 201
 - breast cancer 92, 249, 255
 - cancerous 61, 254
 - cervical cancer 276
 - colon cancer 36, 228
 - diseased 253
 - endothelial 26, 56, 60, 190–91, 194, 197, 205
 - eukaryotic 193
 - gastric cancer 126
 - gastrointestinal tract 254
 - glioblastoma 256
 - hepatic cancer 247
 - human lung carcinoma 246
 - immune system 193
 - infected 52
 - inflammatory 52, 57, 190
 - intestinal 226
 - malignant 185
 - mammalian 124
 - mast 85
 - melanoma 84, 92–93, 126
 - microglial 190
 - multipotent 89
 - necrotic 48
 - non-tumor 228
 - oral cancer 249
 - ovarian cancer 249
 - phagocytic 76
 - prostate cancer 61, 89
 - retinoblastoma 247
 - tumor 34–36, 54, 56–57, 76, 84, 86–90, 95–96, 107, 123, 127–28, 200, 207–8, 211, 225, 254–56, 274, 278, 280, 283, 286, 296

- central composite design (CCD) 297, 299
- cervical cancer treatment 89
- checkpoint blockade, immune 105, 108
- checkpoint inhibition 111, 125, 127–28
- checkpoint inhibitors 113–14, 124–29
 - antitumor effects of 126
- chemokines 85
- chemoresistance, tumor cell 188
- chemotherapeutic efficacy,
 - anti-glioma 92
- chemotherapeutics 16, 23–24, 34, 186, 224
- chemotherapy 30, 37, 46, 106, 125, 144–45, 151, 187–88, 191, 202–3, 236, 250, 253–54, 256
 - cancer 24
 - conventional 12, 210
- chronic myeloid leukemia (CML) 227, 229
- circulating blood cells, smallest 90
- circulating tumor cells (CTCs) 77, 88, 90, 95
- cisplatin 35, 64, 151, 208, 247, 278, 280
- CLs, *see* cytotoxic lymphocytes
- CML, *see* chronic myeloid leukemia
- CMT, *see* carrier-mediated transport
- CNs, *see* carbon nanotubes
- colitis, dextran sulfate
 - sodium-induced 226–27
- colon 226, 229–30
- colorectal cancer metastasis 129
- colorectal cancers 24, 64, 94, 128, 280
- combination therapy 125, 127, 236, 253
- computer tomography (CT) 14
- contrast agents 4–5, 185, 200, 249
- controlled release 11, 81, 146, 254
- convention enhanced delivery (CED) 208
- copolymers 35, 120, 122
- copper ions 309–10
- copper nanoparticles (CuNPs) 201, 295–96, 298, 303–10
 - biosynthesized/biosynthesis of 299, 303, 306, 308
 - synthesis of 296–97, 299, 301, 310
- CPPs, *see* cell-penetrating peptides
- CSCs, *see* cancer stem cells
- CT, *see* computer tomography
- CTCs, *see* circulating tumor cells
- CuNPs, *see* copper nanoparticles
- cytochrome c 49–50
- cytokines 48, 52, 85, 188
 - anti-inflammatory 227
- cytosol 49–51, 256
- cytotoxicity 45, 56, 65, 92–93, 116, 122, 124, 200, 204–5, 208–10, 225, 237, 271
- cytotoxic lymphocytes (CLs) 52–53, 241
- cytotoxic T-cells 107
- DCs, *see* dendritic cells
- DDSs, *see* drug delivery systems
- death-inducing signaling complex (DISC) 52
- delivery methods 105, 202
- delivery systems
 - cancer drug 221
 - carrier-based drug 118, 130
 - nanoparticle-based 246
 - nanoparticle drug 38
- delivery vehicles, microbubble-based drug 157–58
- dendritic cells (DCs) 78, 84–85, 107, 110, 123, 129, 188

- DISC, *see* death-inducing signaling complex
- DLS, *see* dynamic light scattering
- DNA damage 58, 209, 248
- docetaxel 35, 151
- doxorubicin 27, 29–30, 33–34, 82, 84, 88, 94, 151, 202, 206–7, 225, 228–29, 247, 256, 280
- drug delivery
- anticancer 85
 - brain 193, 198, 205
 - carrier-based 117, 130
 - conventional tumor-targeting 77
 - microbubble cavitation 158
- drug delivery systems (DDSs) 1, 3–4, 10–11, 54–55, 76, 79, 116–18, 120–22, 204–5, 248, 272
- drug resistance 210–11, 254
- drugs
- anticancer 5, 35, 47, 56, 62, 119, 188, 191, 197, 229, 248, 254
 - antitumor 56, 193, 195, 277, 288
 - chemotherapeutic 12, 38, 47, 54, 228–29
 - chemotherapy 151
 - cytostatic 247
 - cytotoxic 248
 - DNA-based 116
 - encapsulated 9, 13, 55, 202, 226
 - hydrophilic 124
 - hydrophobic 12
 - lipophilic 30
 - nano-based 46–47
- dynamic light scattering (DLS) 8, 224
- edible plant cells 229
- EGFR, *see* epidermal growth factor receptor
- endocytosis 25, 193, 196–97, 201, 208
- bulk-phase 193
- endoplasmic reticulum 48–49, 53
- endostatin 151
- endothelial cells, tumor-associated 211
- entrapment efficiency 7–9
- epidermal growth factor receptor (EGFR) 36, 189, 199, 202–4, 249
- erythrocyte membranes 81, 84, 86
- erythrocytes 76–77, 79–81, 91, 93, 95
- drug-loaded 120–21
- ESWL, *see* extracorporeal shock wave lithotripsy
- exosomes, mammalian 223
- extracorporeal shock wave lithotripsy (ESWL) 144
- FA, *see* folic acid
- fatty acids 27–28, 31
- fenestrations 23, 191–92
- FGF, *see* fibroblast growth factor
- fibroblast growth factor (FGF) 56, 190
- fibroblasts, cancer-associated 95
- folic acid (FA) 51, 59, 83, 201, 225, 228, 248, 255
- GDNs, *see* grapefruit-derived exosome-like NPs
- GELNs, *see* grape exosome-like NPs
- gene delivery 146, 148, 157
- gene therapy 249–50, 256, 258
- genetic alterations 46
- genotoxicity 209

- ginger 222, 224, 227–29
- glioblastoma 199, 280
- glioma cells 92–93, 126, 189–90, 192, 200, 207–8
- gliomagenesis 189
- gliomas, malignant 185–86
- gold nanoparticles (AuNPs/GNPs)
 - 60–61, 123, 128, 152, 162, 235–58, 278, 287
 - acid-conjugated 248, 256
 - applications of 237, 240, 249, 251, 253, 255
 - β -cyclodextrin-modified dendrimer-entrapped 256
 - cancer radiation therapy 250
 - cancer therapy 250
 - chemotherapy 254
 - functionalization of 244–46, 257
 - functionalized 244–45, 247–49, 255
 - gene therapy 256
 - monodisperse 241, 243
 - optical properties of 238
 - photodynamic therapy 253
 - photothermal therapy 252
 - spherical 236
 - targeted delivery 254
 - toxicity 235, 256–57
- gold nanoshells (AuNSs) 88, 94
 - membrane-coated DOX-loaded 94
- gold salts 242–43
- granzymes 48, 53
- grape 222–23, 226–27
 - oral administration of 226
- grape exosome-like NPs (GELNs) 223, 226
- grapefruit 222, 224–25, 227, 229
- grapefruit-derived exosome-like NPs (GDNs) 223
- graphene 201–2
- graphite 7
- hemagglutinin 36–37
- hepatocellular carcinoma 59, 281
- hepatocyte growth factor (HGF) 190
- HGF, *see* hepatocyte growth factor
- HIFU, *see* high-intensity focused ultrasound
- HIFU cancer therapy 145–46
- HIFU cancer treatment 145
- HIFU-related cancer therapy 145
- high-intensity focused ultrasound (HIFU) 144–45, 151–52
- HIV, *see* human immunodeficiency virus
- honey 295–300, 302–6, 308–10
- HSA, *see* human serum albumin
- human immunodeficiency virus (HIV) 205
- human serum albumin (HSA) 206
- hydrogels 119–20, 125, 199
- hydrophobic interactions 86, 148, 245
- hyperthermia 61–62, 94, 151–52, 188, 252–53
 - nanoparticle-mediated 61
- hypertonic solutions 194–95
- IBD, *see* inflammatory bowel disease
- imiquimod 93, 127
 - nanoparticle adjuvant 127
- immune checkpoint inhibition 105, 109, 111, 113
- immune checkpoint inhibition therapy 105–6
- immune checkpoint inhibitors 105–6, 108, 110–12, 114, 116, 118, 120, 122, 124–30
 - delivery of 105–6, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128–30

- nanoparticle delivery of 124–25, 127, 129
- immune checkpoints 108, 111
- immune reactions 107, 116, 123, 129–30
- immune responses 77, 79, 84, 92, 96, 106–8, 110, 122, 125–27, 129, 188, 198–99, 253, 280
 - anticancer 111
- immunopotentiating reconstituted influenza virosomes (IRIVs) 36
- immunotherapy 105–6, 188, 236
- immunotoxicity 229–30
- inertial cavitation 150, 155
- infections, chronic viral 110–11
- inflammatory bowel disease (IBD) 222, 226
- insulin 197, 206
- intestine 226–27
- intranasal delivery 194, 202
- IRIVs, *see* immunopotentiating reconstituted influenza virosomes
- irradiation 82, 93

- lactic-co-glycolic acid 82–83, 88, 94
- LDLs, *see* low-density lipoproteins
- leukemia 81, 280–81
- leukocyte membranes 85–87, 95
- leukocytes 76–77, 85–88, 95, 190
- leuko-like vector (LLVs) 86, 88
- LIFU, *see* low-intensity focused ultrasound
- LIFU cancer therapy 146
- ligand-targeted particulate nanomedicines 33–34
- lipid peroxidation 209
- lipids, ginger-derived 228
- liposomal doxorubicin 33
 - pegylated 27
- liver 55, 94, 124, 146, 248, 257
- LLVs, *see* leuko-like vector
- localized surface plasmon resonance (LSPR) 239, 252
- low-density lipoproteins (LDLs) 121, 206
- low-intensity focused ultrasound (LIFU) 144–45
- LSPR, *see* localized surface plasmon resonance
- lungs cancer cells line 276
- lymphocytes 85, 188

- macrophages 25, 55, 81, 84–88, 110, 193, 198, 205
 - intestinal 226–27
- magnetic heating 61
- magnetic nanoparticles (MNs) 1, 4–5, 7, 91
- magnetic resonance imaging (MRI) 5, 14, 89, 145, 151, 187, 208
- major histocompatibility class I (MHC I) 107
- mannitol 194
- MAPK, *see* mitogen-activated protein kinase
- MCF-7, breast cancer cell line 83
- MCF-7 breast cancer cells 91
- melanoma 81–82, 106, 113, 126, 129, 281
- membranes, mitochondrial 50–51, 53
- mesenchymal stem cells (MSC) 76–78, 89
- mesoporous silica nanoparticles (MSNs) 30, 162
- metallic nanoparticles, inorganic 236

- MHCI, *see* major histocompatibility class I
- mitochondrial outer membrane permeabilization (MOMP) 49–50
- mitochondrial pathway 49–50, 52, 58
- mitogen-activated protein kinase (MAPK) 59–60, 281
- MNs, *see* magnetic nanoparticles
- MOMP, *see* mitochondrial outer membrane permeabilization
- mononuclear phagocyte system (MPS) 25
- MPS, *see* mononuclear phagocyte system
- MRI, *see* magnetic resonance imaging
- MSC, *see* mesenchymal stem cells
- MSNs, *see* mesoporous silica nanoparticles
- nanoparticles
- albumin-bound 28
 - albumin-stabilized 64
 - binary prodrug 129
 - biocompatible ceramic 6
 - cancer cell membrane-based 91
 - carbon 5
 - cell membrane-based 95
 - cell membrane-mimetic 75–76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96
 - ceramic 1, 4–6
 - combination therapy 126
 - drug-loaded 9–10, 13
 - erythrocyte membrane-based 79
 - Fe₃O₄ magnetic 91
 - graphene 201–2
 - hybrid cell membrane 95
 - hybrid cell-membrane-coated 95
 - inorganic 30, 37, 160–62
 - iron oxide 30
 - leukocyte membrane-based 85
 - lipid-based 37
 - membrane-based 91
 - metal 26, 162, 209, 252, 272, 274, 296, 303
 - metallic 30, 200, 202, 257
 - noble metal 272–73, 275, 277, 282
 - noble metal-based 272
 - non-plasmonic 239
 - organic 161
 - photodynamic 91
 - platelet-camouflaged 91
 - platelet membrane-based 90
 - platinum 278
 - PLGA 127, 129
 - polymeric 1, 4–5, 11, 35, 37, 122, 128
 - polystyrene 26
 - siRNAs-loaded 129
 - theranostic 37–38
 - verbascoside-loaded noble metal 271–72, 274, 276, 278, 280, 282–86, 288
 - ZnP-pyro 127
- nanoparticle toxicity 26
- nanosensors 15
- nanotoxicity 209–10
- nanovectors 88, 225, 228
- grapefruit-derived 225
 - natural 225
- nanovesicles, grapefruit-derived 226–27
- NDA, *see* new drug application
- necroptosis 48
- necrosis 47, 52, 61, 200, 253
- neo-antigens 107, 127
- cancer cell 107
- neurodegenerative diseases 46–47

- neutrophils, human 60
- new drug application (NDA) 64
- non-small cell lung cancers (NSCLC) 106, 113
- NSCLC, *see* non-small cell lung cancers
- nucleic acids 13, 28–29, 121, 196, 209, 245–46, 249, 274

- olfactory mucosa 194
- oral squamous cell carcinoma 280–81

- PA, *see* phosphatidic acid
- paclitaxel 27–28, 35, 64, 82, 88, 126, 151, 207, 225, 229
- pathogens 12, 25–26
- PDENs, *see* plant-derived edible nanoparticles
- PDGF, *see* platelet-derived growth factor
- PDGFR, *see* platelet-derived growth factor receptor
- PDL-1 antibodies 111–13, 126–27
- PDLNs, *see* plant-derived lipid nanoparticles
- PEG, *see* poly ethylene glycol
- PET, *see* positron emission tomography
- phosphatidic acid (PA) 223
- plant-derived edible nanoparticles (PDENs) 221–30
- plant-derived lipid nanoparticles (PDLNs) 222, 225
- platelet-derived growth factor (PDGF) 189–90
- platelet-derived growth factor receptor (PDGFR) 189
- platelets 76–77, 90–91
- platinum 28, 271, 274, 278
- PLGA 29, 81–83, 88, 94, 117, 199
- PLGA-based nanoparticles, targeted 35
- poly ethylene glycol (PEG) 27, 30, 35, 123, 128, 148, 198–99, 205, 246–47, 254–55, 287
- polymeric micelle 33, 119–20, 122
- polyol process 243
- porphyrin 160–62, 255
- positron emission tomography (PET) 14
- primary tumor cells 127
 - light-irradiated 127

- radiation therapy 26, 46, 188, 236, 250, 253
- radiotherapy 106, 121, 125, 187–88, 203, 211, 236, 248, 278
- RBC cloaking 81–82
- RBC membrane 81–82, 84
- reactive nitrogen species (RNS) 57–58
- reactive oxygen species (ROS) 57–58, 61, 63, 85, 156, 159, 161, 209–10, 255
- receptor-mediated transcytosis 205–6
- red blood cells 80, 82
 - empty 83
- RNS, *see* reactive nitrogen species
- ROS, *see* reactive oxygen species

- SAED, *see* selected area electron diffraction
- scanning probe microscopy (SPM) 224

- selected area electron diffraction (SAED) 298, 305
- silica nanoparticles 7, 30
 - mesoporous 30, 94, 162
- silver 30, 63, 271, 274
- silver nanoparticles (AgNPs) 60–61, 63, 278, 287
- SLNs, *see* solid lipid nanoparticles
- solid lipid nanoparticles (SLNs) 124
- sonodynamic therapy 144, 146, 158, 161–63
- sonosensitive nanoparticles
 - applications 164
- sonosensitizer nanocarriers 160, 162
- sonosensitizers 145, 159–62
- SPM, *see* scanning probe microscopy
- stem cells 203, 227, 253
 - intestinal 226
 - mesenchymal 76–78, 89
- TAA, *see* tumor-associated antigens
- targeted delivery/targeted drug delivery 1, 4, 12, 33–34, 36, 118, 121, 125, 144, 158, 200, 228, 236, 249, 254, 258, 272
- T cell activation 107–8, 110–11
- T cell exhaustion 110–11
- theranostic applications 37
- therapeutic efficacy 11, 77, 86, 89, 224
- tissues
 - cancerous 62, 205
 - noncancerous 12, 204
- TNF, *see* tumor necrosis factor
- TNF α 52
- TNF receptor-associated death domain (TRADD) 52
- TRADD, *see* TNF
 - receptor-associated death domain
- transmission electron microscopy 223, 295, 298, 305
- tumor-associated antigens (TAAs) 127
- tumor cell lines 227, 280
- tumor development 16, 189
- tumor endothelium cells 85
- tumor growth 34–36, 88–89, 128, 207, 225, 229
- tumor microenvironment 90, 95, 129, 151, 210
- tumor necrosis factor (TNF) 29, 33, 51–52, 90, 190
- tumor progression 37, 90, 93, 152, 211–12
- tumor reduction 30, 252
- tumors
 - bladder 107
 - drug-resistant 91
 - hypoxic 82
 - residual 253
- tumor vaccine efficacy 123
- tumor vasculature 23, 26, 56, 91, 197
- UCAs, *see* ultrasound contrast agents
- ultrasound
 - contrast-enhanced 146
 - higher intensity 145, 158
- ultrasound cavitation 146
- ultrasound contrast agents (UCAs) 156
- ultrasound irradiation 157, 162

- ultrasound thermal delivery 151
- unfolded protein response (UPR)
 - 53, 58
- UPR, *see* unfolded protein response
- UV irradiation 82, 287

- vascular endothelial growth factor (VEGF) 56, 189–91, 195, 208
- vascular endothelial growth factor receptor (VEGFR) 189, 191
- vascular permeability 156, 190, 192, 195, 197

- VEGF, *see* vascular endothelial growth factor
- VEGFR, *see* vascular endothelial growth factor receptor
- verbascoside 272, 279–82
- virosomes 36–37

- white blood cells 85

- xanthene 160
- X-ray diffraction analysis 295, 298, 306

